# Safety and Efficacy of ThisCART22 in Patients With Refractory or Relapsed B Cell Malignancies

> **NCT04601181** · PHASE1 · UNKNOWN · sponsor: **Fundamenta Therapeutics, Ltd.** · enrollment: 20 (estimated)

## Conditions studied

- B Cell Malignancy

## Interventions

- **BIOLOGICAL:** ThisCART22 cells injection

## Key facts

- **NCT ID:** NCT04601181
- **Lead sponsor:** Fundamenta Therapeutics, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-23
- **Primary completion:** 2022-10-15
- **Final completion:** 2023-10-15
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04601181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04601181, "Safety and Efficacy of ThisCART22 in Patients With Refractory or Relapsed B Cell Malignancies". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04601181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*